Pre-clinical genome editing
Providing a centralised hub for the innovation, application and use of state–of–the–art genome editing technologies in vitro and in vivo.
The Pre-Clinical Genome Editing (PGE) facility leverages cutting-edge genome editing technologies, including CRISPR, to accelerate translational cancer research. As a centralised hub for innovation, we are passionate about understanding and applying state-of-the-art molecular tools to cancer research. Our multidisciplinary team combines in vitro and in vivo expertise to generate authentic disease models that better reflect true clinical conditions. By using these advanced models in complex, patient-relevant preclinical trials, we aim to accelerate clinical translation.
We match the right technology to each researcher’s unique biological questions, recognising that the advancement of technology and biology is symbiotic – each propelling the other forward.
Since 2015, as Cancer Research UK’s first dedicated genome engineering team, we have completed over 900 projects, establishing a strong reputation in the field. Our Pre-Clinical Genome Editing facility offers unparalleled breadth in services, spanning both in vitro and in vivo platforms to provide a comprehensive integrated approach to genome editing and pre-clinical research.
Dr Alasdair Russell
Core Facility Manager
Technologies
Functional Genomics
We leverage state-of-the-art CRISPR technologies, including Cas9, Cas12a, PRIME editing, and base editing. Our expertise covers various cellular contexts and complexities, such as mouse and human models, primary cells, stem cells, cancer cells, organoids, and patient-derived xenografts. We work at scale, using library–based approaches, to integrate perturbation with companion technologies, such as single-cell RNA sequencing, to derive maximal insight.
Transgenics
Our transgenics services create novel models that allow researchers to interrogate human disease more accurately. Using advanced techniques like embryo manipulation, pronuclear injection, and electroporation, we support diverse research needs. Our capabilities extend to rederivation, cryopreservation, and import/export of genetically modified models.
Pre-Clinical Trials
Our Small Animal Hospital (SAH) specialises in complex, multimodal therapeutic trials for cancer research, using genetically engineered mice, xenografts, and orthotopic models. We study cancers of the brain, head and neck, lung, breast, pancreas, and prostate. Our trials include chemotherapy, radiotherapy, hormone therapy, and targeted antibody therapies, supported by sophisticated imaging and sample retrieval techniques.
By seamlessly integrating in vitro and in vivo research, we ensure that every project has the capacity for maximal translational impact, driving forward meaningful advancements in the field.
Related News
See all news-
New immune pathway offers treatment hope for childhood brain tumours
3rd February 2026
A newly discovered immune pathway could lead to gentler treatments for multiple childhood brain cancers, according to new research from our Gilbertson Group published today in Nature Genetics.
Find out more -
Institute scientists uncover molecular switch that drives pancreatic cancer progression
30th October 2025
New research from our Carroll Group has identified a molecular mechanism that helps explain how pancreatic ductal adenocarcinoma progresses, offering a potential path toward more targeted treatments.
Find out more -
CI scientists shortlisted for Innovation & Entrepreneurship Awards
29th November 2022
Institute researchers and spin-out companies have been shortlisted for the Cancer Research Horizons Innovation & Entrepreneurship Awards.
Find out more
Further reading
Pre-clinical Genome Editing contributed to the Institute’s LEAF Silver accreditation, see the Sustainability webpage for more information.